Damages in patent reform
This article was originally published in The Gray Sheet
Executive Summary
Legislative reforms addressing how damages are awarded in patent infringement litigation is unnecessary based on a review of jury verdicts in 93 court cases between 2005 and 2007, says the device industry-backed Innovation Alliance. The Feb. 13 1report argues that guidelines currently used to calculate damages work well, and judges effectively review verdicts for appropriateness. The device industry is opposed to a so-called "apportionment provision" that passed in House patent reform bill H.R. 1908 last fall, which it fears could limit damages unfairly. According to AdvaMed CEO Steve Ubl, the Senate's discussion on the apportionment provision in companion bill S. 1145 is fluid (2"The Gray Sheet" Feb. 4, 2008, p. 18). Reports are that the Senate is now unlikely to take up the bill before late March
You may also be interested in...
Patent Bill Damages Provision Still Up For Debate – Senate Committee Report
A Senate Judiciary Committee 1report on a pending patent reform bill suggests a controversial provision on calculating infringement damages is still ripe for revision, but bill authors will not stray too far from their original intent
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.